159 related articles for article (PubMed ID: 35232318)
1. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database.
O'Flynn R; Zhou YP; Waskin H; Leong R; Straus W
Expert Opin Drug Saf; 2022 Aug; 21(8):1113-1120. PubMed ID: 35232318
[TBL] [Abstract][Full Text] [Related]
2. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
3. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
4. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
Lo Re V; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Haynes K; Roy JA; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA
Am J Med; 2016 Mar; 129(3):283-91.e5. PubMed ID: 26597673
[TBL] [Abstract][Full Text] [Related]
5. Clinical hepatotoxicity associated with antifungal agents.
Kyriakidis I; Tragiannidis A; Munchen S; Groll AH
Expert Opin Drug Saf; 2017 Feb; 16(2):149-165. PubMed ID: 27927037
[TBL] [Abstract][Full Text] [Related]
6. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
7. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
8. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
Van Daele R; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
[TBL] [Abstract][Full Text] [Related]
10. Successful challenge of voriconazole in a patient with posaconazole-associated minor drug eruption: A case report.
Weeraphon B; Vanichanan J; Usayaporn S
J Clin Pharm Ther; 2020 Dec; 45(6):1486-1488. PubMed ID: 32686229
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.
Moton A; Krishna G; Wang Z
J Clin Pharm Ther; 2009 Jun; 34(3):301-11. PubMed ID: 19646076
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury: an unusual complication of posaconazole use.
Otu A; Bongomin F; Kosmidis C; Denning DW
J Chemother; 2018; 30(6-8):380-383. PubMed ID: 30663547
[TBL] [Abstract][Full Text] [Related]
13. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
14. Association of adverse effects with high serum posaconazole concentrations.
Jensen K; Saleh OA; Chesdachai S; Jannetto PJ; Mara KC; Yetmar ZA; Rivera CG
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37537152
[TBL] [Abstract][Full Text] [Related]
15. Antifungal agents and liver toxicity: a complex interaction.
Tverdek FP; Kofteridis D; Kontoyiannis DP
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):765-76. PubMed ID: 27275514
[TBL] [Abstract][Full Text] [Related]
16. Combining K-72 Hepatic Failure with 15 Individual T-Codes to Identify Patients with Idiosyncratic Drug-Induced Liver Injury in the Electronic Medical Record.
Louissaint J; Kassab I; Yeboah-Korang A; Fontana RJ
Dig Dis Sci; 2022 Aug; 67(8):4243-4249. PubMed ID: 34427818
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole in immunocompromised pediatric patients.
Vicenzi EB; Cesaro S
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
